Ruriko Tanaka

894 total citations
23 papers, 727 citations indexed

About

Ruriko Tanaka is a scholar working on Hematology, Molecular Biology and Genetics. According to data from OpenAlex, Ruriko Tanaka has authored 23 papers receiving a total of 727 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Hematology, 11 papers in Molecular Biology and 10 papers in Genetics. Recurrent topics in Ruriko Tanaka's work include Chronic Myeloid Leukemia Treatments (15 papers), Chronic Lymphocytic Leukemia Research (8 papers) and Eosinophilic Disorders and Syndromes (6 papers). Ruriko Tanaka is often cited by papers focused on Chronic Myeloid Leukemia Treatments (15 papers), Chronic Lymphocytic Leukemia Research (8 papers) and Eosinophilic Disorders and Syndromes (6 papers). Ruriko Tanaka collaborates with scholars based in Japan, United States and Australia. Ruriko Tanaka's co-authors include Shinya Kimura, Eishi Ashihara, Taira Maekawa, Miki Takeuchi, Asumi Yokota, Itsuro Shimada, Rika Saito, Masamichi Mori, Yoko Ueno and Sadao Kuromitsu and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Ruriko Tanaka

23 papers receiving 711 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ruriko Tanaka Japan	14	357	346	199	159	103	23	727
Maria Alessandra Santucci Italy	17	432 1.2×	296 0.9×	112 0.6×	136 0.9×	40 0.4×	49	740
L. H. Hoefsloot Netherlands	8	240 0.7×	206 0.6×	117 0.6×	99 0.6×	80 0.8×	9	645
Victoria Grandage United Kingdom	9	492 1.4×	472 1.4×	147 0.7×	177 1.1×	92 0.9×	16	926
Galit Granot Israel	13	290 0.8×	206 0.6×	103 0.5×	83 0.5×	64 0.6×	28	503
Yongwei Su China	13	563 1.6×	302 0.9×	82 0.4×	86 0.5×	59 0.6×	27	688
A M Martelli Italy	10	580 1.6×	198 0.6×	91 0.5×	191 1.2×	89 0.9×	17	785
Terry J. Gaymes United Kingdom	13	585 1.6×	280 0.8×	105 0.5×	265 1.7×	80 0.8×	24	800
Kerstin Maria Kampa-Schittenhelm Germany	12	283 0.8×	155 0.4×	80 0.4×	171 1.1×	90 0.9×	30	516
Kanteti V. Prasad United States	12	380 1.1×	226 0.7×	152 0.8×	167 1.1×	149 1.4×	14	697
E. P. Reddy United States	6	201 0.6×	127 0.4×	97 0.5×	216 1.4×	147 1.4×	11	483

Countries citing papers authored by Ruriko Tanaka

Since Specialization

Citations

This map shows the geographic impact of Ruriko Tanaka's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ruriko Tanaka with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ruriko Tanaka more than expected).

Fields of papers citing papers by Ruriko Tanaka

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ruriko Tanaka. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ruriko Tanaka. The network helps show where Ruriko Tanaka may publish in the future.

Co-authorship network of co-authors of Ruriko Tanaka

This figure shows the co-authorship network connecting the top 25 collaborators of Ruriko Tanaka. A scholar is included among the top collaborators of Ruriko Tanaka based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ruriko Tanaka. Ruriko Tanaka is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Mori, Masamichi, Naoki Kaneko, Yoko Ueno, et al.. (2017). Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia. Investigational New Drugs. 35(5). 556–565. 200 indexed citations

Mori, Masamichi, Naoki Kaneko, Yoko Ueno, et al.. (2014). ASP2215, a novel FLT3/AXL inhibitor: Preclinical evaluation in acute myeloid leukemia (AML).. Journal of Clinical Oncology. 32(15_suppl). 7070–7070. 24 indexed citations

Mori, Masamichi, Sadao Kuromitsu, Yoko Ueno, et al.. (2012). Abstract 866: ASP3026, a selective ALK inhibitor, induces tumor regression in a crizotinib-refractory model and prolongs survival in an intrapleurally xenograft model. Cancer Research. 72(8_Supplement). 866–866. 7 indexed citations

Tanaka, Ruriko, Shinya Kimura, Eishi Ashihara, et al.. (2011). Rapid automated detection of ABL kinase domain mutations in imatinib-resistant patients. Cancer Letters. 312(2). 228–234. 15 indexed citations

Nagao, Rina, Eishi Ashihara, Shinya Kimura, et al.. (2011). Growth inhibition of imatinib-resistant CML cells with the T315I mutation and hypoxia-adaptation by AV65 – a novel Wnt/β-catenin signaling inhibitor. Cancer Letters. 312(1). 91–100. 18 indexed citations

Ashihara, Eishi, Yoko Nakagawa, Takahiro Kiuchi, et al.. (2010). A combination of a DNA-chimera siRNA against PLK-1 and zoledronic acid suppresses the growth of malignant mesothelioma cells in vitro. Cancer Letters. 294(2). 245–253. 13 indexed citations

Kawata, Eri, Eishi Ashihara, Yoko Nakagawa, et al.. (2010). Galectin‐9 ameliorates acute GVH disease through the induction of T‐cell apoptosis. European Journal of Immunology. 41(1). 67–75. 40 indexed citations

Takeuchi, Miki, Eishi Ashihara, Yohko Yamazaki, et al.. (2010). Rakicidin A effectively induces apoptosis in hypoxia adapted Bcr‐Abl positive leukemic cells. Cancer Science. 102(3). 591–596. 33 indexed citations

Yokota, Asumi, Shinya Kimura, Ruriko Tanaka, et al.. (2009). Osteoclasts are involved in the maintenance of dormant leukemic cells. Leukemia Research. 34(6). 793–799. 14 indexed citations

10.

Yokota, Asumi, Shinya Kimura, Ruriko Tanaka, et al.. (2009). Osteoclasts Are Involved in the Maintenance of Dormant Leukemic Cells.. Blood. 114(22). 4245–4245. 1 indexed citations

11.

Takeuchi, Miki, Shinya Kimura, Junya Kuroda, et al.. (2009). Hypoxia-Adapted CML Cells Are More Primitive Population and Are Eradicated by Glyoxalase-1 Inhibitors.. Blood. 114(22). 2166–2166. 3 indexed citations

12.

Ashihara, Eishi, Shinya Kimura, Kazumasa Takenaka, et al.. (2008). Administration of PLK-1 small interfering RNA with atelocollagen prevents the growth of liver metastases of lung cancer. Molecular Cancer Therapeutics. 7(9). 2904–2912. 47 indexed citations

13.

Kuroda, Junya, Yuri Kamitsuji, Shinya Kimura, et al.. (2008). Anti-myeloma effect of homoharringtonine with concomitant targeting of the myeloma-promoting molecules, Mcl-1, XIAP, and β-catenin. International Journal of Hematology. 87(5). 507–515. 48 indexed citations

14.

Tanaka, Ruriko, Matthew Squires, Shinya Kimura, et al.. (2008). Activity of the Multi-Targeted Kinase Inhibitor, AT9283 on Imatinib-Resistant CML Models.. Blood. 112(11). 1104–1104. 6 indexed citations

15.

Kuroda, Junya, Yosuke Matsumoto, Ruriko Tanaka, et al.. (2008). JAK2V617F-Positive Essential Thrombocythemia and Multiple Myeloma with IGH/CCND1 Gene Translocation Coexist, but Originate from Separate Clones. Acta Haematologica. 120(3). 177–181. 11 indexed citations

16.

Tanaka, Ruriko & Shinya Kimura. (2008). Abl tyrosine kinase inhibitors for overriding Bcr–Abl/T315I: from the second to third generation. Expert Review of Anticancer Therapy. 8(9). 1387–1398. 34 indexed citations

17.

Yokota, Asumi, Shinya Kimura, Ruriko Tanaka, et al.. (2008). Roles of Osteoclasts in Leukemic Cells. Blood. 112(11). 3184–3184. 1 indexed citations

18.

Nagao, Rina, Shinya Kimura, Eishi Ashihara, et al.. (2008). A Novel β-catenin Inhibitor, AV65 Suppresses the Growth of CML Cell Lines Which Acquire Imatinib-Resistance Because of Abl Kinase Domain Mutations Including T315I and Hypoxia-Adaptation.. Blood. 112(11). 1081–1081. 3 indexed citations

19.

Tanaka, Ruriko, Junya Kuroda, William Stevenson, et al.. (2008). Fully automated and super-rapid system for the detection of JAK2V617F mutation. Leukemia Research. 32(9). 1462–1467. 26 indexed citations

20.

Kuroda, Junya, Shinya Kimura, Michael Andreeff, et al.. (2007). ABT‐737 is a useful component of combinatory chemotherapies for chronic myeloid leukaemias with diverse drug‐resistance mechanisms. British Journal of Haematology. 140(2). 181–190. 70 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact